- Investing Ideas
- /
- Mexican Pharmaceuticals & Biotech Potentially Undervalued Companies
Mexican Pharmaceuticals & Biotech Potentially Undervalued Companies
UPDATED Mar 11, 2024
Companies with a Value score of at least 3, ordered by Value score
59 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 4503 NAstellas Pharma | JP¥204.11 | 0% | n/a | JP¥2.9t | JP¥273.59 | PE682.5x | E41.1% | 4.4% | ||
| AMGN *Amgen | US$4,705.00 | 0% | 12.0% | US$146.7b | US$5,188.35 | PE22x | E9.2% | 3.3% | ||
| ATOS *Atossa Therapeutics | US$20.40 | 16.9% | 59.4% | US$150.4m | US$77.92 | PB1.5x | E61.3% | n/a | ||
| BMY *Bristol-Myers Squibb | US$905.00 | 3.5% | -26.3% | US$109.9b | US$919.82 | PE13.7x | E7.6% | 4.4% | ||
| BAYN NBayer | €541.80 | 0% | -52.7% | €26.3b | €789.78 | PB0.8x | E43.2% | 0.4% | ||
| SAN1 NSanofi | €1,629.20 | 0% | -11.4% | €115.5b | €1,878.23 | PE12.7x | E5.7% | 3.9% | ||
| QURE NuniQure | US$118.63 | 0% | n/a | US$302.2m | US$569.41 | PS2.7x | E23.6% | n/a | ||
| SOBI NSwedish Orphan Biovitrum | kr567.34 | 0% | 0% | kr64.7b | kr746.39 | PE20.4x | E15.6% | n/a | ||
| MIRM *Mirum Pharmaceuticals | US$479.15 | 0% | 12.5% | US$1.3b | US$803.41 | PS7x | E64.2% | n/a | ||
| SNY NSanofi | €807.56 | 1.5% | -5.8% | €110.3b | €976.93 | PE20.4x | E14.0% | 4.3% | ||
| ROG NRoche Holding | CHF4,459.55 | 0.9% | -16.0% | CHF194.4b | CHF5,214.07 | PE16.8x | E8.4% | 4.0% | ||
| GSK NGSK | UK£701.70 | 0.2% | n/a | UK£68.0b | UK£821.65 | PE13.8x | E9.2% | 3.5% | ||
| BCRX *BioCryst Pharmaceuticals | US$98.86 | 0% | n/a | US$1.1b | US$226.71 | PS3.3x | E65.8% | n/a | ||
| ENDPQ NEndo International | US$169.00 | 0% | n/a | US$19.2m | US$2,068.54 | PE-0.006x | n/a | n/a | ||
| IONS *Ionis Pharmaceuticals | US$900.00 | 0% | n/a | US$6.4b | US$1,160.38 | PS8.1x | E27.9% | n/a | ||
| AGIO *Agios Pharmaceuticals | US$397.93 | 0% | -12.8% | US$1.7b | US$525.41 | PS64.5x | E29.4% | n/a | ||
| 2269 NWuXi Biologics (Cayman) | HK$62.53 | 0% | n/a | HK$73.9b | HK$158.25 | PE16.3x | E17.2% | n/a | ||
| BHC NBausch Health Companies | US$145.86 | 0% | n/a | US$3.3b | US$156.51 | PE-5.6x | E110.0% | n/a | ||
| REGN *Regeneron Pharmaceuticals | US$16,380.00 | 0% | 21.5% | US$104.1b | US$17,114.52 | PE26.3x | E9.1% | n/a | ||
| JNJ *Johnson & Johnson | US$2,706.20 | -1.5% | -7.3% | US$384.2b | US$2,924.54 | PE29.1x | E9.3% | 3.0% | ||
| PHM1 NPharma Mar | €1,608.38 | 0% | 0% | €601.5m | €2,866.23 | PE20.9x | E26.7% | 2.0% | ||
| FOLD *Amicus Therapeutics | US$208.80 | 0% | n/a | US$3.2b | US$287.56 | PS9.8x | E61.4% | n/a | ||
| ALNY *Alnylam Pharmaceuticals | US$2,620.00 | 0% | -21.9% | US$18.9b | US$3,878.51 | PS10.3x | E60.8% | n/a | ||
| JAZZ NJazz Pharmaceuticals | US$2,027.24 | 0% | -28.4% | US$7.3b | US$3,247.88 | PE17.5x | E15.5% | n/a |